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me  have  recently  witnessed  a  remarkable  progress
n our  understanding  of  molecular  biology  and
ignalling pathways  of  NSCLC  cells  which  resulted
n ErbB  targeted  therapies,  ALK  inhibitors  and
ther targeted  agents  being  now  in  clinical  trials.
owever,  a  substantial  number  of  NSCLC  patients
emain  non-responsive  or  relapse  early  on  these
argeted  therapies.  Improved  understanding  of  the
unctioning  of  ErbB  receptor  family  have  led  to
econd  generation  active  anti-ErbB  therapies.  It  is
lear from  different  preclinical  and  clinical  studies
hat combined  anti-ErbB  therapies  have  a  superior
fﬁcacy  to  single  agent  therapies.
In future  it  will  be  essential  to  characterize
utations  of  resistance  in  each  line  of  treatment.
irculating tumour  cells  and  plasma  DNA  analysis
ould  enable  us  to  obtain  this  information  eas-
er. The  development  of  the  resistance  can  be
lonal/thus  not  present  at  all  the  tumour  sites,
upporting a  concept  of  continuing  the  targeted
reatment even  beyond  tumour  progression.  Co-
argeting  molecular  pathways  such  as  P13K-AKT
nd/or RAS-ERK  and/or  T790M  or  c-Met  along  with
rbB receptors  may  result  in  more  optimal  anti-
ancer  effects.
We need  to  better  understand  the  interplay
etween various  oncogenes  and  tumour  suppressors
a
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ttp://dx.doi.org/10.1016/j.jiph.2012.09.007nd  thus  identify  key  molecular  pathways  for  the
reatments.  Understanding  the  reasons  for  toxi-
ities of  targeted  therapies  will  be  important  for
ur future  rational  approaches  in  combining  or
equencing  different  targeted  agents.  Co-targeting
eceptors and  their  ligand  synthesis  might  help
liminating  more  effectively  receptor  activation
nd downstream  oncogenic  signalling.  New  insights
f autocrine  activation  of  receptors  might  lead  to
ew therapeutic  approaches.
The  past  successes  and  failures  of  therapies  led
o development  of  new  generation  irreversible  ErbB
amily inhibitors  and  the  discovery  of  new  tar-
ets, i.e.  EML4—ALK  fusion  gene,  ROS,  RET  and
thers, which  offer  signiﬁcant  improvements  in
linical outcome  for  a  speciﬁc  group  of  patients.
he combined  regimen  strategies  of  ﬁrst  generation
rbB family  inhibitors  with  anti  c-MET  inhibitors
re being  tested  in  ongoing  clinical  trials  in  hope
o further  improve  therapeutic  effect.  We  have
o target  multiple  pivotal  players  of  malignant
ells on  individual  basis  and  in  each  line  of  treat-
ent, in  order  to  replace  ‘‘chemotherapy  to  ﬁt
ll’’ by  personalized  medicine  and  thus  conquer
SCLC.
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